

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-37. (Canceled)

38. (Previously presented) A polynucleotide encoding a fusion protein which is stable in a cell, said fusion protein comprising:

(a) a first (poly)peptide which is unstable in a cell; and

(b) a second (poly)peptide, which is a viral T antigen carrying at least one of an internal deletion or a C-terminal deletion and which co-precipitates a chaperone, wherein said chaperone is hsp73.

39. (Previously presented) The polynucleotide of claim 38, wherein said first (poly)peptide comprises at least one of an epitope, a functional domain of a protein, a structural domain of a protein, a mutated variant of a protein or a truncated variant of a protein.

40. (Previously presented) The polynucleotide of claim 38, wherein at least one of the function or the structure of the N-terminal J domain of said viral T antigen is maintained.

41. (Previously presented) The polynucleotide of claim 38, wherein said viral T antigen is a viral large T antigen.

42. (Previously presented) The polynucleotide of claim 38, wherein said viral T antigen is SV40 T antigen.

43. (Previously presented) The polynucleotide of claim 41, wherein said viral large T antigen is SV40 large T antigen.

44. (Previously presented) The polynucleotide of claim 43, wherein about 300 C-terminal amino acids of said SV40 large T antigen are deleted.

45. (Previously presented) The polynucleotide of claim 43, wherein said SV40 large T antigen contains amino acids 1 to 272.

46. (Previously presented) The polynucleotide of claim 43, wherein the internal deletion comprises at least part of the nuclear localisation signal.

47. (Previously presented) The polynucleotide of claim 46, wherein amino acids 110 to 152 are deleted.

48. (Previously presented) The polynucleotide of claim 38 further encoding a tag.

49. (Previously presented) The polynucleotide of claim 38, wherein said first and second (poly)peptide are linked via a protease cleavage site.

50. (Previously presented) A vector comprising the polynucleotide of claim 38.

51. (Previously presented) A host cell comprising the polynucleotide of claim 38 or a vector comprising said polynucleotide.

52. (Previously presented) A method for the production of a fusion protein, said method comprising:

(a) culturing the host cell comprising the polynucleotide of claim 38 under conditions that allow the synthesis of said fusion protein; and

(b) recovering said fusion protein from the culture.

53. (Previously presented) The method of claim 52 further comprising the step of separating said fusion protein from complexed chaperones.

54. (Canceled)

55. (Previously presented) A method for the production of a first (poly)peptide which is unstable in a cell, said method comprising:

(a) culturing the host cell comprising the polynucleotide of claim 38 under conditions that allow the synthesis of a fusion protein, wherein said first and second (poly)peptide are linked via a protease cleavage site;

(b) recovering said fusion protein from the culture; and

(c) separating said second (poly)peptide from said fusion protein by proteolytic cleavage.

56. (Previously presented) A method for the production of a complex comprising a fusion protein and a chaperone, said method comprising:

(a) culturing the host cell comprising the polynucleotide of claim 38 under conditions that allow complex formation of said fusion protein with said chaperone; and

(b) recovering said complex from the culture.

57. (Currently amended) A method for the production of an antibody directed against a first (poly)peptide which is unstable in a cell, said method comprising administering to a subject in an amount sufficient to induce a humoral immune response to at least one of the polynucleotide of claim 38; and a vector comprising said polynucleotide.

58. (Currently Amended) A method of immunizing a subject, said method comprising administering to a subject in an amount sufficient to induce at least one of a humoral immune response, a cellular immune response or a combination thereof to at least one ~~of the~~ polynucleotide of claim 38; and a vector comprising said polynucleotide.

59. (Currently Amended) A kit comprising at least one of:

(a) the polynucleotide of claim 38;

(b) a vector comprising said polynucleotide; and

(c) a host cell comprising said polynucleotide or a vector comprising said polynucleotide.

60. (Currently Amended) A diagnostic composition comprising at least one ~~of the~~ polynucleotide of claim 38, and a vector comprising said polynucleotide.

61. – 63. (Canceled)

64. (Currently Amended) A pharmaceutical composition comprising at least one ~~of the~~ polynucleotide of claim 38, and a vector comprising said polynucleotide.

65. (Previously presented) The pharmaceutical composition of claim 64 which is a vaccine.

66. (Previously presented) The pharmaceutical composition of claim 65, wherein said vaccine induces a humoral immune response, a cellular immune response or a combination thereof.